Efsitora alfa shows A1C reduction in type 2 diabetes patients

Eli Lilly and Company announced the results of the QWINT-2 phase 3 trial on September 10, 2024, which evaluated the efficacy of once-weekly insulin efsitora alfa in adults with type 2 diabetes who were insulin-naïve. The trial involved 928 participants from various countries, including the U.S., Brazil, and Japan, and compared efsitora to the once-daily insulin degludec over a 52-week period. The primary goal was to demonstrate that efsitora could effectively reduce A1C levels, achieving results comparable to daily insulin regimens. The findings revealed that participants using efsitora achieved an A1C below 7%, with an additional 45 minutes of time in range per day without increased risk of hypoglycemia. The overall rates of hypoglycemia were low for both treatment groups, indicating that efsitora may offer a safer alternative for managing blood glucose levels. This is particularly significant for patients who struggle with daily insulin compliance due to the complexity of their treatment regimens. Experts noted that the once-weekly dosing of efsitora could simplify diabetes management for many patients, potentially leading to better adherence and improved health outcomes. The results were published in The New England Journal of Medicine and presented at the European Association for the Study of Diabetes Annual Meeting, highlighting the importance of these findings in the ongoing search for innovative diabetes treatments. Eli Lilly aims to redefine diabetes care through advancements in medication that address the needs of diverse patient populations. The promising results from the QWINT-2 trial may pave the way for broader acceptance and use of efsitora in clinical practice, ultimately improving the quality of life for individuals living with type 2 diabetes.